Adrenaline for the Treatment of No-Reflow in Normotensive Patients

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE4

Total Enrollment

201 participants

Study Classification

INTERVENTIONAL

Study Start Date

2021-01-01

Study Completion Date

2021-04-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

No-reflow is defined as the lack of myocardial perfusion despite opening of the epicardial coronary vessels in the setting of percutaneous coronary intervention (PCI). It has been demonstrated that either impaired flow or the absence of flow is associated with an increased rate of mortality. Among available treatment options, intracoronary adenosine is widely used in clinical practice, moreover, adrenaline is a safe alternative for the cases where use of adenosine is limited due to presence of hypotension or bradycardia. Nonetheless, evidence from retrospective and observational studies suggest that intracoronary adrenaline is well tolerated and may exert encouraging effects in prompt recovery of flow in these patients. However, very limited data are available on efficacy of intracoronary (IC) adrenaline in normotensive patients. Therefore, this study is planned to study the hypothesis that; intracoronary adrenaline is safe and has significantly higher efficacy as compared to adenosine for the treatment of no-reflow in normotensive patients with acute coronary syndrome.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Oral Nicorandil for Prevention of No Reflow Phenomenon in Anterior STEMI Patients Undergoing PPCI

NCT07138508

No Reflow Phenomenon Anterior STEMI

COMPLETED PHASE1/PHASE2

Oral Nicorandil in ST Elevation Myocardial Infarction Patients Undergoing Primary Percutaneous Coronary Intervention

NCT04632121

Nicorandil

UNKNOWN

The Effects of Adrenaline and Milrinone in Patients With Myocardial Dysfunction After CABG

NCT00446017

Cardiac Output, Low

COMPLETED PHASE3

Reversal of Complete Heart Block With Aminophylline in Inferior Wall Myocardial Infarction Patients

NCT05666219

Complete Heart Block Inferior Wall Myocardial Infarction

WITHDRAWN PHASE4

Hyperemic Efficacy of IV Adenosine in HFrEF

NCT03235700

Heart Failure With Reduced Ejection Fraction Coronary Artery Disease

UNKNOWN NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Acute Coronary Syndrome No-Reflow Phenomenon Normotensive

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Treatment group

Patients receiving intracoronary adrenaline

Group Type EXPERIMENTAL

Adrenaline

Intervention Type DRUG

Treatment group will receive adrenaline (100 to 400 mcg) for the treatment of No-reflow

Control group

Patients receiving intracoronary adenosine

Group Type ACTIVE_COMPARATOR

Adenosine

Intervention Type DRUG

Control group will receive adenosine (100 to 400 mcg)

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Adrenaline

Treatment group will receive adrenaline (100 to 400 mcg) for the treatment of No-reflow

Intervention Type DRUG

Adenosine

Control group will receive adenosine (100 to 400 mcg)

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* All patients with acute coronary syndrome who developed No-reflow during PCI.
* Patients with systolic blood pressure of \> 100 mmHg.

Exclusion Criteria

* Hypotensive patients
* Patients with Valvular or congenital heart disease.
* Patients with Atypical chest pain
* Patients with Cardiomyopathy
* Patients with Pericarditis
* Patients with Myocarditis
* Patients refused to give consent

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No